GSK head joins Nabriva as chief medical officer

pharmafile | May 26, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Elyse Seltzer, GSK, Nabriva Therapeutics 

Austrian-based clinical stage biopharma firm Nabriva Therapeutics has appointed Dr Elyse Seltzer as its chief medical officer.

Seltzer assumes the role from Dr William Prince, who will transition to senior vice president of its clinical science division. 

She joins Nabriva from GlaxoSmithKline where she was vice president of global clinical sciences and operations, and prior to joining GSK was chief medical officer at Tengion, a regenerative medicine company.

Seltzer has also held roles at Centocor and Vicuron, but began her in the anti-infectives clinical R&D unit at SmithKline Beecham (now GSK).

Dr Colin Broom who is the firm’s chief executive, says: “We are very pleased to welcome Elyse to Nabriva. We have established a world class clinical development leadership team to advance our pipeline with a sense of urgency to address areas of significant medical need.”

Seltzer adds: “I am thrilled to join Nabriva. I am excited to have the opportunity to advance a novel class of antibacterials, particularly given the current and evolving challenges around resistance to currently available antibiotics. I look forward to working with the highly experienced clinical team to fulfil this goal.”

Related Content


GSK shares data from global shingles survey

GSK has announced data from its new global survey about shingles. The data suggests that …


GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

GSK has announced positive results from a planned interim efficacy analysis of the phase 3 …

GSK’s low carbon inhaler, Ventolin, progresses to phase 3 trials 

GSK has announced that in 2024 it intends to start phase 3 trials of a …

Latest content